life science investing Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
life science investing Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
life science investing Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
life science investing Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
life science investing Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
life science investing Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
life science investing CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
